Boston Scientific Corporation $BSX Shares Purchased by CENTRAL TRUST Co

CENTRAL TRUST Co increased its stake in Boston Scientific Corporation (NYSE:BSX) by 22.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,096 shares of the medical equipment provider’s stock after purchasing an additional 2,624 shares during the quarter. CENTRAL TRUST Co’s holdings in Boston Scientific were worth $1,514,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Sound Income Strategies LLC boosted its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter worth about $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific during the first quarter worth approximately $27,000. Princeton Global Asset Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in Boston Scientific by 72.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 145 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BSX. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Truist Financial boosted their price target on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. BTIG Research reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $123.77.

Insiders Place Their Bets

In other news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $104.12 on Thursday. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The company has a market cap of $154.34 billion, a PE ratio of 55.68, a P/E/G ratio of 2.02 and a beta of 0.58. The stock has a 50 day simple moving average of $99.85 and a 200-day simple moving average of $102.54. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.